Morepen Laboratories Ltd

- Morepen Laboratories is currently evaluating various fundraising options for resource augmentation, including capacity expansion and working capital needs. - The company is debt-free and has been approached by multiple banks for debt raising; discussions are ongoing but no final decisions have been made yet. - Future capex plans amount to Rs. 200 to 250 Crores over the next 2-3 years across API, medical devices, and formulations divisions, which may require additional financing. - The financial team is working on finalizing plans, and the company is open to debt or equity fundraising depending on market conditions and performance. - No specific details or timelines about new fundraising through debt or equity have been disclosed yet; the company is at an evaluation stage.

- Capex plans span across API, medical devices, and formulations. - API segment capex planned around Rs.125 Crores. - Medical devices capex estimated at Rs.50 Crores. - Formulation capex roughly Rs.40 Crores. - Total capex plus working capital in next 2-3 years expected between Rs.200 Crores to Rs.250 Crores. - Current capacity expansions funded from internal accruals (e.g., Rs.50 Crores spent in last 9 months). - Additional API capacity planned: 250 KL within next 12 months. - Working capital augmentation planned due to 20-25% expected growth. - Company is debt-free but open to debt raising and evaluating multiple financing options. - No final fundraising decisions yet; resource augmentation and capacity building are under evaluation. - Focus on zero liquid discharge (ZLD) plant approval for environmental compliance.

- Morepen Laboratories targets a steady growth rate in revenue and volumes. - API segment expected to grow at a CAGR of 17%-18%, potentially up to 20%-25% with capacity expansions. - Medical devices showing strong growth, around 24% quarterly and 37% over nine months, with plans to increase distribution. - Formulation business is a new growth driver, having grown 40% in the recent quarter, expected to double to around Rs.500 Crores in three years. - Dr. Morepen OTC brand currently flat/fluctuating due to limited marketing investments but new innovative products are planned for launch. - Overall growth target ranges from 20%-25% annually. - Capacity expansions underway: Rs.125-150 Crores in API, Rs.50 Crores in medical devices, Rs.40 Crores in formulations. - Focus on internal accruals for funding, with fundraising plans under evaluation. - Aim to maintain and improve EBITDA and PAT margins with operational efficiencies and product mix improvements.

- EBITDA margins are expected to rise by 150 to 200 basis points annually over the next few years, moving from around 12% to potentially double digits by FY2026. - Profit After Tax (PAT) is anticipated to increase from about 6% to 8-10% by FY2026, reflecting steady margin improvement. - EPS for the current year is around Rs.2+ if the current quarter's performance sustains, indicating strong growth prospects. - Revenue growth is targeted at 16-17% for the current year with aspirations to reach 20-25% CAGR in the next 2-3 years. - Operating margins (EBITDA) are expected to stabilize in early double digits, contributing positively to bottom-line growth. - The company is focusing on capacity expansion and new product launches to fuel future profit and earnings growth. - Working capital and capex needs may prompt resource augmentation, but the firm remains debt-free and open to financing options.

- The transcript does not provide explicit details on the current or expected order book or pending orders for Morepen Laboratories Limited. - However, the company mentions: - Strong growth and increasing production, with a 37%-40% increase in quantity produced over nine months. - Capacity utilization is high (90%-95% in API, peak levels in devices and formulations). - Ongoing capacity expansions and investments in API, medical devices, and formulations to support growth. - Capex plans of Rs. 200-250 Crores over 2-3 years indicating preparation for increased orders. - No specific figures on outstanding or pending orders are discussed during the call.